Business

Know the Business — Novonesis

Bottom line. Novonesis is a global near-monopoly in industrial enzymes and microbial cultures — a fermentation-based ingredient business where a tiny bottle of bugs and proteins drops into a customer's process and shifts yield, energy use, or product quality by a few percent. The company prints 36%+ adjusted EBITDA margins, grows organically 5–9% a year, and is a decisive #1 in most of its end markets. The market's tension today: a stellar operating business has been half-buried under a EUR 12B Chr. Hansen merger — goodwill is now 37% of assets, reported ROIC has collapsed from 19% to 6%, and the real debate is whether the combined entity can deliver the promised revenue synergies on top of already-booked cost savings.

1. How This Business Actually Works

Novonesis sells catalysts — literal or biological — that let customers get more output from the same inputs. The end customer (Unilever, Coca-Cola, Danone, Bunge, POET) does not buy "enzymes"; they buy 1% higher cheese yield, 30% less surfactant in laundry detergent, or extra ethanol per bushel of corn. The enzyme is 1–2% of the customer's bill of materials but protects 100% of the end product's performance. That asymmetry is the entire economic story.

Why the margins are so high. The strain library is the moat: microbes selected and engineered over 80+ years, producing enzymes no one else can match on activity-per-gram or thermal stability. Customers design their factory process around a specific enzyme; switching means re-running months of trials and re-certifying with regulators or retailers. That is the gross margin: 53.9% reported, 59.1% adjusted. R&D at ~11% of sales is essentially a permanent tax that protects those margins — stop spending and the library ages, as Novozymes learned when Chinese generic enzyme producers came for the commoditizing end of the portfolio around 2018–2020.

Incremental profit is lopsided. Once a fermentation line is built, marginal cost of another batch is close to variable raw-material and utilities. That's why the FY2025 adjusted EBITDA margin hit 37.1% and is guided to grind higher — volume leverage plus merger cost synergies (80% of run-rate already booked in year one). The constraint is capacity, not demand: capex ran 11.3% of sales in 2025 and is guided to stay elevated for planetary-health expansion.

2. The Playing Field

Novonesis sits at the top of a small, concentrated pyramid. Only three companies matter in enzymes globally — Novonesis (~48% share), IFF (post-DuPont N&B, ~20%), and a long tail of Chinese producers (Vland, Sunson, Longda, collectively ~15%). In cultures, Novonesis and Chr. Hansen were the two global players; the merger collapsed the duopoly into a monopoly with ~70% global share in dairy cultures and ~50% in probiotics.

What the peer set reveals. The flavors-and-fragrances camp (Givaudan, IFF, dsm-firmenich) looks similar on the surface — also ingredient-IP businesses — but their margins sit 15–20 points below Novonesis. Why the gap? F&F plays in consumer flavors where brand and application development compete against lower technical switching costs; customers can reformulate. Novonesis plays in process enzymes and cultures where switching requires revalidating an entire industrial process or meeting regulatory safety rules for infant formula or pharma. IFF's FY2025 numbers are the cautionary tale: the DuPont N&B deal created a business too diverse to manage, ROIC is negative, and EBITDA margin is less than half Novonesis'.

Novonesis' relative weakness: customer concentration in certain divisions (detergents: Procter & Gamble + Unilever + Henkel are ~50% of Household Care sales) and heavy dependence on emerging-market ethanol production for the Planetary Health growth engine. Kerry is the best-run mid-cap peer operationally but doesn't touch industrial enzymes. The takeaway: there is no real second source for what Novonesis sells — the closest peer (Chr. Hansen) now sits inside the company.

3. Is This Business Cyclical?

Much less cyclical than "Specialty Chemicals" suggests — more like a slow-beating consumer staple with two cyclical tails. The core business (detergents, dairy, probiotics, infant nutrition) is tied to daily consumption and was resilient through 2008, 2015, and 2020. The cyclical tails are bioenergy (ethanol demand tracks gasoline demand and crop prices) and Human Health / Dietary Supplements (sensitive to US consumer discretionary spending and retailer destocking). Working capital can absorb 1–2% of revenue in a destocking year, which you saw in the Plant agriculture division in 2024.

Read the chart this way. Margins dip but rarely collapse — worst trough was 2023 at 33.2% when the fossil-energy cost spike from Russia's invasion of Ukraine hit Danish and Spanish fermentation plants (gas-intensive), and simultaneously customers worked down inventory built during COVID. Organic growth troughed at 0% (2020) and 5% (2023). This is not cyclical like basic chemicals; this is "growth can pause, margins compress by 300bps." The cycle hit was in volume and raw-material spreads, not in pricing — management held price through both shocks.

Where you actually should worry. The business is not recession-cyclical but it is exposed to: (1) ethanol policy and crop margins in the US/Brazil — Planetary Health's Energy subarea is ~12% of group sales and double-digit growth is priced in; (2) Chinese dairy consumption, which has been declining since 2022 and hit the Food & Beverages division's Dairy subarea; (3) emerging-market FX translation — ~36% of sales are emerging markets and 2025 organic growth of 7% was reported as only 5% in EUR once currency hit.

4. The Metrics That Actually Matter

Five numbers explain this stock. The consensus ratios do not. Forget P/E — merger-accounting noise (PPA amortization, one-time inventory step-up) will distort reported earnings for the next 5–7 years. Watch these instead.

Read this scorecard. Growth is stable in a tight band. Margin is structurally expanding. ROIC ex-goodwill is the most interesting — it fell from 21% pre-merger to 10% post-merger because the dsm-firmenich feed enzyme business was bought at a premium (EUR 1.5B for ~EUR 200M of EBITDA, absorbed in 2025). Management target is to work ROIC back to mid-teens via synergy realization over 2026–2028. If they hit it, the multiple re-rates; if they don't, the stock is a dead weight that earns a 5% cash return.

What consensus watches but you should discount. Reported EPS — distorted by ~EUR 235M/yr of PPA amortization. Reported ROIC including goodwill — mechanically penalized by the merger regardless of operating performance. Gross margin — dropped from 57.7% to 47.2% in 2024 purely from PPA inventory step-up, while adjusted gross margin actually rose from 54.3% to 59.1%. These optics have already scared off some generalist funds, which is part of the setup if the thesis works.

5. What I'd Tell a Young Analyst

Watch three things, ignore most of the noise, and understand where the thesis breaks.

Watch: (1) Revenue synergy delivery. Management has promised sales synergies on top of the cost synergies mostly already banked — plausibly EUR 200M of high-margin revenue by 2028. Each quarterly call will disclose a synergy number; the cost side has been over-delivered, the revenue side is unproven because it requires actually cross-selling Novozymes enzymes to Chr. Hansen dairy customers, which sales organizations rarely execute well post-merger. (2) Household Care deceleration. FY2025 Household Care growth was a structural outlier at 13%, driven by an unusual European detergent-volume recovery. Guidance is for normalization — if it re-accelerates, there is real upside; if it goes to 3% you know the 2024 number was a pull-forward. (3) dsm-firmenich feed enzyme ramp. EUR 1.5B acquisition closed 2025 and goes inside Planetary Health. Early signal of whether the acquisition playbook works for bolt-ons, or whether Novonesis only knows how to buy other Danish biotech companies well.

Ignore: P/E, reported ROIC including goodwill, any broker model that compares Novonesis with Evonik or BASF. They are not peers. The reference frame is Givaudan on economics, Linde on capital intensity, and Nestlé on customer stickiness.

What would genuinely change the thesis. A sustained drop in organic growth below 4% for two consecutive years, because it would mean the ingredient moat is eroding — that is the only way this business becomes interesting to short. Also: a second generic enzyme breakthrough from Chinese producers hitting industrial laundry, which would force Novonesis to lean on volume and R&D output to defend share. And: any sign that management dilutes the pure-play strategy with a non-biosolutions acquisition. The focus on fermentation-and-nothing-else is half of what produces the 37% margin. If Ester Baiget or her successor starts buying chemical businesses, the multiple should compress immediately.